These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 31336602)

  • 41. Novel Therapeutics Against Breast Cancer Stem Cells by Targeting Surface Markers and Signaling Pathways.
    Das PK; Rakib MA; Khanam JA; Pillai S; Islam F
    Curr Stem Cell Res Ther; 2019; 14(8):669-682. PubMed ID: 31808385
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
    Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
    Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endocrine therapy--current benefits and limitations.
    Nicholson RI; Johnston SR
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth.
    Saran U; Chandrasekaran B; Tyagi A; Shukla V; Singh A; Sharma AK; Damodaran C
    Front Pharmacol; 2023; 14():1150774. PubMed ID: 36909163
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Rios-Fuller TJ; Ortiz-Soto G; Lacourt-Ventura M; Maldonado-Martinez G; Cubano LA; Schneider RJ; Martinez-Montemayor MM
    Oncotarget; 2018 Nov; 9(89):35907-35921. PubMed ID: 30542507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications.
    Ordaz-Ramos A; Tellez-Jimenez O; Vazquez-Santillan K
    Front Cell Dev Biol; 2023; 11():1221175. PubMed ID: 37492224
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcriptomic but not genomic variability confers phenotype of breast cancer stem cells.
    Tong M; Deng Z; Yang M; Xu C; Zhang X; Zhang Q; Liao Y; Deng X; Lv D; Zhang X; Zhang Y; Li P; Song L; Wang B; Al-Dherasi A; Li Z; Liu Q
    Cancer Commun (Lond); 2018 Sep; 38(1):56. PubMed ID: 30231942
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
    Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
    Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
    Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heterogeneity and Plasticity of Breast Cancer Stem Cells.
    Sousa B; Ribeiro AS; Paredes J
    Adv Exp Med Biol; 2019; 1139():83-103. PubMed ID: 31134496
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium.
    Feng ZM; Qiu J; Chen XW; Liao RX; Liao XY; Zhang LP; Chen X; Li Y; Chen ZT; Sun JG
    BMC Cancer; 2015 Sep; 15():645. PubMed ID: 26400441
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biological mechanisms and clinical implications of endocrine resistance in breast cancer.
    Giuliano M; Schifp R; Osborne CK; Trivedi MV
    Breast; 2011 Oct; 20 Suppl 3():S42-9. PubMed ID: 22015292
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differences in stemness properties associated with the heterogeneity of luminal-type breast cancer.
    Ito T; Sato N; Yamaguchi Y; Tazawa C; Moriya T; Hirakawa H; Hayashi S
    Clin Breast Cancer; 2015 Apr; 15(2):e93-103. PubMed ID: 25481840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
    Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
    Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
    Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
    J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.